19. December 2024 | Corporate News

Marinomed Biotech AG: Extraordinary general meeting approves sale of Carragelose division

  • Required majority of shareholders vote in favour of the sale of the Carragelose business unit
  • Proceeds from the sale ensure implementation of the restructuring plan and commercialization of the Marinosolv platform
  • Dr. Karl Mahler elected to the Supervisory Board

 

The full press release is available here:

Marinomed Biotech AG: Extraordinary general meeting approves sale of Carragelose division
(54 KB)